Two of its biggest sellers — Eliquis and cancer immunotherapy Opdivo — will lose patent exclusivity in the coming years. Cancer blockbuster Revlimid has been suffering from generic competition ...

The anticlotting drug, Eliquis, has been approved for use in the United States by the country’s regulatory body, the Food and Drug Administration (FDA). Eliquis is manufactured by Bristol-Myers ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...